Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Tongji Hospital
Tianjin Medical University Cancer Institute and Hospital
Tianjin Medical University Cancer Institute and Hospital
M.D. Anderson Cancer Center
Sir Run Run Shaw Hospital
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Fudan University
NYU Langone Health
University of Southern California
The Affiliated Hospital of Qingdao University